ZyVersa Therapeutics (ZVSA) Competitors $0.61 +0.00 (+0.02%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. BFRI, ADXN, MYNZ, RNAZ, OMGA, INDP, AIM, APLM, SLXN, and AYTUShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Biofrontera (BFRI), Addex Therapeutics (ADXN), Mainz Biomed (MYNZ), TransCode Therapeutics (RNAZ), Omega Therapeutics (OMGA), Indaptus Therapeutics (INDP), AIM ImmunoTech (AIM), Apollomics (APLM), Silexion Therapeutics (SLXN), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Biofrontera Addex Therapeutics Mainz Biomed TransCode Therapeutics Omega Therapeutics Indaptus Therapeutics AIM ImmunoTech Apollomics Silexion Therapeutics Aytu BioPharma ZyVersa Therapeutics (NASDAQ:ZVSA) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment. Is ZVSA or BFRI more profitable? ZyVersa Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. ZyVersa Therapeutics' return on equity of -224.85% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets ZyVersa TherapeuticsN/A -224.85% -103.22% Biofrontera -36.31%-565.73%-96.64% Does the media favor ZVSA or BFRI? In the previous week, ZyVersa Therapeutics had 4 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for ZyVersa Therapeutics and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.89 beat ZyVersa Therapeutics' score of 0.09 indicating that Biofrontera is being referred to more favorably in the news media. Company Overall Sentiment ZyVersa Therapeutics Neutral Biofrontera Very Positive Do institutionals & insiders have more ownership in ZVSA or BFRI? 3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 0.3% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 0.2% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer ZVSA or BFRI? Biofrontera has a consensus price target of $7.00, indicating a potential upside of 900.00%. Given Biofrontera's stronger consensus rating and higher possible upside, analysts plainly believe Biofrontera is more favorable than ZyVersa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ZVSA or BFRI? Biofrontera received 5 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 66.67% of users gave Biofrontera an outperform vote. CompanyUnderperformOutperformZyVersa TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesBiofronteraOutperform Votes866.67% Underperform Votes433.33% Which has more volatility & risk, ZVSA or BFRI? ZyVersa Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Which has stronger earnings & valuation, ZVSA or BFRI? Biofrontera has higher revenue and earnings than ZyVersa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZyVersa TherapeuticsN/AN/A-$98.30MN/AN/ABiofrontera$37.32M0.17-$20.13M-$2.26-0.31 SummaryBiofrontera beats ZyVersa Therapeutics on 9 of the 15 factors compared between the two stocks. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.72M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.5118.48Price / SalesN/A242.70395.68103.60Price / CashN/A65.8538.1834.62Price / Book0.016.516.774.25Net Income-$98.30M$143.21M$3.22B$248.23M7 Day Performance-14.71%1.98%1.45%0.89%1 Month Performance3.81%6.89%3.97%3.53%1 Year Performance-88.36%-2.52%16.14%5.08% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics0.3149 of 5 stars$0.61+0.0%N/A-88.5%$1.58MN/A0.002Gap DownBFRIBiofrontera2.9118 of 5 stars$0.81-4.7%$7.00+764.2%-62.0%$7.19M$37.32M-0.3670ADXNAddex Therapeutics2.3781 of 5 stars$6.75-10.0%$30.00+344.4%+1.8%$7.16M$556,045.00-19.8530Short Interest ↓News CoverageGap UpMYNZMainz Biomed2.9792 of 5 stars$3.07-4.7%$14.00+356.0%-90.3%$7.12M$893,991.00-0.0530Short Interest ↓Gap UpRNAZTransCode Therapeutics3.0982 of 5 stars$0.30+10.1%$10.00+3,233.3%-99.9%$7.00MN/A0.009Short Interest ↓News CoveragePositive NewsGap UpHigh Trading VolumeOMGAOmega Therapeutics1.9142 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.4%$6.92M$8.10M-0.09120Gap UpINDPIndaptus Therapeutics3.453 of 5 stars$0.46-3.1%$8.50+1,728.4%-78.8%$6.71MN/A-0.276Short Interest ↓Negative NewsAIMAIM ImmunoTech1.682 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.6%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeAPLMApollomics2.0645 of 5 stars$5.91-0.7%$200.00+3,284.1%-84.5%$6.57M$1.22M0.0045Gap DownSLXNSilexion TherapeuticsN/A$0.72-3.8%$5.00+592.8%N/A$6.52MN/A0.00N/AAYTUAytu BioPharma1.691 of 5 stars$1.03+2.0%N/A-52.0%$6.36M$77.23M-0.71160Positive News Related Companies and Tools Related Companies BFRI Alternatives ADXN Alternatives MYNZ Alternatives RNAZ Alternatives OMGA Alternatives INDP Alternatives AIM Alternatives APLM Alternatives SLXN Alternatives AYTU Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZVSA Stock Free ZVSA Stock Alerts